SCHEMBL6024162

SCHEMBL6024162

c1ccc2c(c1)Cc1c(cccc1N1CSc3ccccc31)N2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.36
MEN1 O00255 3/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.36
AHR P35869 1/20 0.36
PDK2 Q15119 1/20 0.36
NPC1 O15118 1/20 0.36
HSP90AA1 P07900 1/20 0.36
THRB P10828 1/20 0.36
HK1 P19367 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
GALK1 P51570 1/20 0.36
BLM P54132 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
GAA P10253 2/20 0.33
CYP1A2 P05177 1/20 0.33
BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15196679 0.69 MAPT (0.56) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL88280 0.69 MAPT (0.47) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL29896031 0.69 MAPT (0.47) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL29757969 0.68 NPC1 (0.50) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL6024420 0.67 ALDH1A1 (0.36) MAPTKMT2AKDM4EGAATDP1
SCHEMBL16470043 0.66 HSD17B10 (0.42) MEN1MAPTKMT2AKDM4ENPC1
SCHEMBL25275193 0.65 MAPT (0.47) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL7516634 0.65 MEN1 (0.47) SRCMEN1MAPTKMT2AKDM4E
SCHEMBL16470683 0.65 MEN1 (0.50) MEN1KMT2AKDM4EPOLBNOX1
SCHEMBL5141694 0.65 NPC1 (0.47) SRCMEN1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1353908-B1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN INC (US) 2006-03-08 EP disclosed
EP-1353908-A4 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN INC (US) 2004-01-28 EP disclosed
EP-1353908-A1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN, INC. (US) 2003-10-22 EP disclosed
WO-2002059096-A1 PROCESSES AND SYNTHETIC INTERMEDIATES FOR PREPARING N-ARYLACRIDANCARBOXYLIC ACID DERIVATIVES LUMIGEN, INC. (US) 2002-08-01 WO disclosed
US-6410732-B2 FORMATION OF BOND BETWEEN NITROGEN ATOM OF ACRIDAN RING AND CARBON ATOM OF ANOTHER AROMATIC OR HETEROAROMATIC RING COMPOUND; ASSAYS FOR PEROXIDASE ENZYMES AND ENZYME INHIBITORS AND IN ASSAYS EMPLOYING ENZYME-LABELED SPECIFIC BINDING PAIRS LUMIGEN, INC. 2002-06-25 US disclosed
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives LUMIGEN, INC. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031869-A1 Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives ALDH3A1, AADAC, SPR SRC 2615/4885MEN1 4540/4885MAPT 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.